The first insulin patch pump in Europe is now available in the UK, providing continuous insulin treatment without tubing.
The mylife™ OmniPod® from Ypsomed is a continuous insulin infusion system. It offers insulin-dependent diabetics improved comfort and flexibility, and could greatly improve the treatment of children with diabetes.
The compact pump is fastened directly onto the skin with an adhesive, and is controlled using a Personal Diabetes Manager (PDM) device that also serves as a blood glucose meter.
The mylife OmniPod is available nationwide in the UK and Germany via specialist diabetes clinics.
Simon Michel, Senior Vice President of Marketing & Sales at Ypsomed, said: "With the mylife OmniPod insulin patch pump, Ypsomed is the first provider to bring the very latest technology in insulin treatment to Europe, just six months after announcing the partnership with Insulet Corporation. We are pleased to enable people with diabetes to enjoy greater comfort and a better quality of life through our products."
Conventional insulin pumps require a set of infusion tubes. With the mylife OmniPod, the cannula is positioned automatically at the touch of a button. The pump is entirely patched on the skin. It is not visible under clothing, and can be used during swimming and other exercise.
Switching to the mylife OmniPod has enabled diabetes patients to improve their long-term glycaemic control by avoiding interruptions to their insulin supply. The Personal Diabetes Manager (PDM) helps to determine the amount of insulin required by the patient.
The OmniPod System has been available in the USA since 2006, where thousands of patients now use it.
Based in Switzerland, the Ypsomed Group is a leading supplier of injection systems. Ypsomed Ltd is based in Selby, Yorkshire.
mylife OmniPod